Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | F13A1 | P00488 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | TGM1 | P22735 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1119158 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL31525951 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL3195518 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL20361649 | 0.91 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL70762 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2621382 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL70761 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2621378 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL17076715 | 0.89 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL15183635 | 0.89 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1992613-B1 | PROCESS FOR PRODUCTION OF 3,4-DISUBSTITUTED PYRROLIDINE DERIVATIVE AND INTERMEDIATE FOR THE PRODUCTION | KYORIN SEIYAKU KK (JP) | 2013-01-30 | — | — | EP | disclosed |
| US-8084622-B2 | stereoselective asymmetric hydrogenation of 1-protected-4-alkoxycarbonyl-3-oxopyrrolidine, followed by ester hydrolysis, followed by amidation with cyclopropylamine; production of (3R,4S)-3-cyclopropylaminomethyl-4-fluoropyrrolidine useful as an intermediate to novel antibiotics | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-8084622-B2 | stereoselective asymmetric hydrogenation of 1-protected-4-alkoxycarbonyl-3-oxopyrrolidine, followed by ester hydrolysis, followed by amidation with cyclopropylamine; production of (3R,4S)-3-cyclopropylaminomethyl-4-fluoropyrrolidine useful as an intermediate to novel antibiotics | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-8084622-B2 | stereoselective asymmetric hydrogenation of 1-protected-4-alkoxycarbonyl-3-oxopyrrolidine, followed by ester hydrolysis, followed by amidation with cyclopropylamine; production of (3R,4S)-3-cyclopropylaminomethyl-4-fluoropyrrolidine useful as an intermediate to novel antibiotics | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20100056805-A1 | Process for producing 3,4-disubstituted pyrrolidine derivative and production intermediate thereof | GOTOH TAKAYUKI | 2010-03-04 | — | — | US | disclosed |
| US-20100056805-A1 | Process for producing 3,4-disubstituted pyrrolidine derivative and production intermediate thereof | GOTOH TAKAYUKI | 2010-03-04 | — | — | US | disclosed |
| US-20100056805-A1 | Process for producing 3,4-disubstituted pyrrolidine derivative and production intermediate thereof | GOTOH TAKAYUKI | 2010-03-04 | — | — | US | disclosed |
| US-7667049-B2 | Process for producing 3,4-disubstituted pyrrolidine derivative and production intermediate thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7667049-B2 | Process for producing 3,4-disubstituted pyrrolidine derivative and production intermediate thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7667049-B2 | Process for producing 3,4-disubstituted pyrrolidine derivative and production intermediate thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20090023935-A1 | Process for Producing 3,4-Disubstituted Pyrrolidine Derivative and Production Intermediate Thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20090023935-A1 | Process for Producing 3,4-Disubstituted Pyrrolidine Derivative and Production Intermediate Thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20090023935-A1 | Process for Producing 3,4-Disubstituted Pyrrolidine Derivative and Production Intermediate Thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1992613-A1 | PROCESS FOR PRODUCTION OF 3,4-DISUBSTITUTED PYRROLIDINE DERIVATIVE AND INTERMEDIATE FOR THE PRODUCTION | Kyorin Pharmaceutical Co., Ltd. (JP) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023935-A1 | Process for Producing 3,4-Disubstituted Pyrrolidine Derivative and Production Intermediate Thereof | HPD, DHPS, HAAO | SMN1; SMN2 4424/4885NPC1 3882/4885RAB9A 2365/4885 |
| US-20100056805-A1 | Process for producing 3,4-disubstituted pyrrolidine derivative and production intermediate thereof | HPD, DHPS, HAAO | SMN1; SMN2 4424/4885NPC1 3882/4885RAB9A 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.